probiome Sign in
← Conditions CancersDigestive system

Liver cancer (hepatocellular carcinoma)

Compared within 1 study that had both: 25 people with liver cancer (hepatocellular carcinoma) and 76 healthy people. 3 microbes are less common in people with liver cancer (hepatocellular carcinoma), and 5 more common.

A difference is an association: it doesn’t mean these microbes cause, prevent or treat liver cancer (hepatocellular carcinoma).

Phylum

Searching opens both lists and shows only matching rows.

Less common in liver cancer (hepatocellular carcinoma) · 3

Strongest first, then the biggest gap · Each figure is 10 people Strongest first · Each figure is 10 people
  1. Adlercreutzia equolifaciens in 1 study Healthy 49% liver cancer (hepatocellular carcinoma) 12%
  2. Roseburia intestinalis in 1 study Healthy 66% liver cancer (hepatocellular carcinoma) 28%
  3. Blautia faecis in 1 study Healthy 91% liver cancer (hepatocellular carcinoma) 64%

More common in liver cancer (hepatocellular carcinoma) · 5

Strongest first, then the biggest gap · Each figure is 10 people Strongest first · Each figure is 10 people
  1. Limosilactobacillus mucosae in 1 study Healthy 2.6% liver cancer (hepatocellular carcinoma) 36%
  2. Streptococcus gordonii in 1 study Healthy 28% liver cancer (hepatocellular carcinoma) 68%
  3. Faecalibacterium butyricigenerans in 1 study Healthy 16% liver cancer (hepatocellular carcinoma) 52%
  4. Streptococcus vestibularis in 1 study Healthy 6.6% liver cancer (hepatocellular carcinoma) 36%
  5. Ligilactobacillus salivarius in 1 study Healthy 15% liver cancer (hepatocellular carcinoma) 44%

Where these numbers come from

Studies
Only GMrepo projects that had people with the condition and healthy people, 10 or more of each. Numbers come from those studies, never from pooling.Sampled in Thailand.
How common
The share of people whose sample has any of it, in the people with the condition and in the healthy people of those same studies. Tested within studies (Cochran–Mantel–Haenszel, corrected for testing many microbes); a difference counts when it is clear and meaningful (Cohen’s h of 0.2 or more).
Strength word
Counted by code from how many studies point the same way: Seen again and again (3 or more, none clearly the other way), Seen more than once (2, the majority), Seen once (1, listed last). Where studies disagree, a row isn’t listed.
Each study
Tap a row for every study’s own numbers, and for how much carriers have.
Analysis
Our analysis of GMrepo data. GMrepo on Data sources · Read the rules

Also compared · 315 microbes

Compared within studies that had both, but not listed above.

No meaningful difference · 315
PubMed · human studies and reviews first

Recent research

All research on it
  1. Review International journal of molecular sciences · 2026
    Microbiome-Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma.
    PubMed ↗
  2. Review Frontiers in cellular and infection microbiology · 2026
    From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.
    PubMed ↗
  3. Observational Digestive and liver disease · 2026
    Genetically predicted gut bacteria, circulating bacteria-associated metabolites and liver cancer: A Mendelian randomisation study.
    PubMed ↗
  4. Review Cancer biology & medicine · 2026
    How the gut microbiome affects the immunotherapy response in hepatocellular carcinoma.
    PubMed ↗
  5. Observational Journal of gastroenterology and hepatology · 2026
    Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort.
    PubMed ↗

Source: PubMed, U.S. National Library of Medicine · 46 linked papers, last 10 years